secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001104659-23-051393
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx Q1 revenue $8.0M (+96% YoY); US HF sales surge 132%; raises full-year guidance
--------------------------------------------------------------------------------

- Net loss of $11.4M ($0.55 per share) vs $10.0M ($0.49) in prior year quarter.
- U.S. heart failure revenue $6.8M (+132% YoY); active implanting centers grew to 122 (118% YoY).
- FY 2023 revenue guidance raised to $35.5M-$38.0M (prior $35M-$38M); gross margin guidance improved to 80%-83%.
- Q2 2023 revenue expected between $8.2M and $8.8M; operating expenses $76M-$80M for full year.
- Cash and equivalents $103.3M at quarter end; net cash used in ops and investing $10.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465923051393/0001104659-23-051393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465923051393/tm2313916d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-051393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer